| Expression pattern: |
UP |
| Associated gene: |
ADAM17, AGO2 |
| Associated microRNA: |
miR-145-5p |
| Biological function: |
Promotes AngII-induced VSMC phenotype switching, promotes VSMC proliferation, and inhibits VSMC apoptosis. |
| Molecular mechanism: |
circHIPK2 acts as a miR-145-5p sponge to upregulate ADAM17 expression, forming a circHIPK2/miR-145-5p/ADAM17 axis. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes); other pathway/process (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
circHIPK2 may represent a new therapeutic target for hypertension. |
| Description: |
circHIPK2 is a human HIPK2-derived circRNA that is upregulated in aortic VSMCs from hypertensive patients. It promotes AngII-induced VSMC phenotype switching by sponging miR-145-5p and increasing ADAM17 expression, thereby enhancing VSMC proliferation and suppressing apoptosis. The study suggests circHIPK2 as a potential therapeutic target for hypertension. |
| Confidence score: |
0.8203 |